STOCK TITAN

[Form 4] MARIMED INC. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

MariMed (MRMD) insider update: Chief Operating Officer Timothy Shaw reported routine equity transactions on 10/27/2025. He converted 111,112 restricted stock units into common stock (Code M; price $0), then had 32,612 shares withheld to cover taxes (Code F) at $0.1579 per share. Following these transactions, Shaw beneficially owns 9,133,912 shares directly. He also has 2,000,000 shares held indirectly by the Shaw Family Trust. The RSUs were granted on October 27, 2022 and are now fully vested, with no unvested RSUs remaining under that grant.

Aggiornamento interno MariMed (MRMD): Il Chief Operating Officer Timothy Shaw ha riportato operazioni azionarie ordinarie il 27/10/2025. Ha convertito 111.112 unità di azioni vincolate in azioni ordinarie (Codice M; prezzo $0), poi ha trattenuto 32.612 azioni per coprire le imposte (Codice F) a $0,1579 per azione. A seguito di queste operazioni, Shaw detiene beneficiamente direttamente 9.133.912 azioni. Ha inoltre 2.000.000 azioni detenute indirettamente dal Shaw Family Trust. Le RSU sono state concesse il 27 ottobre 2022 e ora sono completamente maturate, non restano RSU non maturate sotto tale assegnazione.

Actualización interna de MariMed (MRMD): El Director de Operaciones Timothy Shaw informó transacciones de acciones rutinarias el 27/10/2025. Convirtió 111,112 unidades de acciones restringidas en acciones ordinarias (Código M; precio $0), luego retuvo 32,612 acciones para cubrir impuestos (Código F) a $0.1579 por acción. Tras estas operaciones, Shaw posee de forma beneficiosa directamente 9,133,912 acciones. También tiene 2,000,000 acciones en posesión indirecta por parte del Shaw Family Trust. Las RSU fueron concedidas el 27 de octubre de 2022 y ahora están plenamente vestidas, sin RSU pendientes de vesting bajo esa adjudicación.

MariMed(MRMD) 내부자 정보 업데이트: 최고운영책임자 Timothy Shaw가 2025년 10월 27일 일상적 자사주 거래를 보고했습니다. 그는 111,112주 제한주식 유닛을 보통주로 전환했고(코드 M; 가격 $0), 이어 32,612주를 세금 보전을 위해 보유 공제(코드 F)로 보유했고, 주당 $0.1579에 매입했습니다. 이 거래 이후 Shaw는 직접적으로 이익 소유 주식 9,133,912주를 보유합니다. 또한 Shaw Family Trust가 간접적으로 2,000,000주를 보유합니다. RSU는 2022년 10월 27일에 부여되었으며 이제 완전히 귀속되어 해당 부여에 대해 미귀속 RSU는 남아 있지 않습니다.

Mise à jour interne MariMed (MRMD) : Le directeur des opérations Timothy Shaw a signalé des transactions d'actions ordinaires routinières le 27/10/2025. Il a converti 111 112 unités d'actions restreintes en actions ordinaires (Code M; prix $0), puis a retenu 32 612 actions pour couvrir les impôts (Code F) à $0,1579 par action. Suite à ces transactions, Shaw détient bénéficiellement directement 9 133 912 actions. Il détient également 2 000 000 actions détenues indirectement par le Shaw Family Trust. Les RSU ont été accordées le 27 octobre 2022 et sont désormais entièrement acquises, sans RSU non acquises restants sous cette attribution.

MariMed (MRMD) Insider-Update: Der Chief Operating Officer Timothy Shaw meldete routinemäßige Aktien-Transaktionen am 27.10.2025. Er hat 111.112 RSUs in Stammaktien umgewandelt (Code M; Preis $0), dann wurden 32.612 Aktien zur Abdeckung der Steuern (Code F) zu $0,1579 pro Aktie einbehalten. Nach diesen Transaktionen besitzt Shaw direkt als wirtschaftlicher Eigentümer 9.133.912 Aktien. Er hält außerdem indirekt über den Shaw Family Trust 2.000.000 Aktien. Die RSUs wurden am 27. Oktober 2022 gewährt und sind nun vollständig vestet, es gibt keine unvested RSUs mehr unter dieser Zuteilung.

تحديث داخلي من MariMed (MRMD): أفاد رئيس العمليات Timothy Shaw بأن هناك معاملات أسهم روتينية في 27/10/2025. قام بتحويل 111,112 وحدة أسهم مقيدة إلى أسهم عادية (الرمز M؛ السعر $0)، ثم حُجز 32,612 سهمًا لتغطية الضرائب (الرمز F) بسعر $0.1579 للسهم. بعد هذه المعاملات، يمتلك شو بشكل فعّال مباشرة 9,133,912 سهمًا. كما لديه 2,000,000 سهمًا مملوكة بشكل غير مباشر بواسطة Shaw Family Trust. تم منح RSU في 27 أكتوبر 2022 وهي الآن مكتملة الاستحقاق، ولا توجد RSU غير مكتملة تحت تلك المنحة.

Positive
  • None.
Negative
  • None.

Insights

Routine RSU vesting with tax withholding; neutral impact.

The filing shows an RSU vest (Code M) of 111,112 shares at $0, typical for time-based awards converting one-for-one into common stock. The subsequent tax event (Code F) withheld 32,612 shares at $0.1579 to satisfy withholding obligations, a standard non-cash settlement.

Post-transaction holdings are 9,133,912 shares direct and 2,000,000 indirect via a trust. This is administrative and does not signal new open-market buying or selling. Actual market impact depends on any future trades, which are not indicated in the excerpt.

Aggiornamento interno MariMed (MRMD): Il Chief Operating Officer Timothy Shaw ha riportato operazioni azionarie ordinarie il 27/10/2025. Ha convertito 111.112 unità di azioni vincolate in azioni ordinarie (Codice M; prezzo $0), poi ha trattenuto 32.612 azioni per coprire le imposte (Codice F) a $0,1579 per azione. A seguito di queste operazioni, Shaw detiene beneficiamente direttamente 9.133.912 azioni. Ha inoltre 2.000.000 azioni detenute indirettamente dal Shaw Family Trust. Le RSU sono state concesse il 27 ottobre 2022 e ora sono completamente maturate, non restano RSU non maturate sotto tale assegnazione.

Actualización interna de MariMed (MRMD): El Director de Operaciones Timothy Shaw informó transacciones de acciones rutinarias el 27/10/2025. Convirtió 111,112 unidades de acciones restringidas en acciones ordinarias (Código M; precio $0), luego retuvo 32,612 acciones para cubrir impuestos (Código F) a $0.1579 por acción. Tras estas operaciones, Shaw posee de forma beneficiosa directamente 9,133,912 acciones. También tiene 2,000,000 acciones en posesión indirecta por parte del Shaw Family Trust. Las RSU fueron concedidas el 27 de octubre de 2022 y ahora están plenamente vestidas, sin RSU pendientes de vesting bajo esa adjudicación.

MariMed(MRMD) 내부자 정보 업데이트: 최고운영책임자 Timothy Shaw가 2025년 10월 27일 일상적 자사주 거래를 보고했습니다. 그는 111,112주 제한주식 유닛을 보통주로 전환했고(코드 M; 가격 $0), 이어 32,612주를 세금 보전을 위해 보유 공제(코드 F)로 보유했고, 주당 $0.1579에 매입했습니다. 이 거래 이후 Shaw는 직접적으로 이익 소유 주식 9,133,912주를 보유합니다. 또한 Shaw Family Trust가 간접적으로 2,000,000주를 보유합니다. RSU는 2022년 10월 27일에 부여되었으며 이제 완전히 귀속되어 해당 부여에 대해 미귀속 RSU는 남아 있지 않습니다.

Mise à jour interne MariMed (MRMD) : Le directeur des opérations Timothy Shaw a signalé des transactions d'actions ordinaires routinières le 27/10/2025. Il a converti 111 112 unités d'actions restreintes en actions ordinaires (Code M; prix $0), puis a retenu 32 612 actions pour couvrir les impôts (Code F) à $0,1579 par action. Suite à ces transactions, Shaw détient bénéficiellement directement 9 133 912 actions. Il détient également 2 000 000 actions détenues indirectement par le Shaw Family Trust. Les RSU ont été accordées le 27 octobre 2022 et sont désormais entièrement acquises, sans RSU non acquises restants sous cette attribution.

MariMed (MRMD) Insider-Update: Der Chief Operating Officer Timothy Shaw meldete routinemäßige Aktien-Transaktionen am 27.10.2025. Er hat 111.112 RSUs in Stammaktien umgewandelt (Code M; Preis $0), dann wurden 32.612 Aktien zur Abdeckung der Steuern (Code F) zu $0,1579 pro Aktie einbehalten. Nach diesen Transaktionen besitzt Shaw direkt als wirtschaftlicher Eigentümer 9.133.912 Aktien. Er hält außerdem indirekt über den Shaw Family Trust 2.000.000 Aktien. Die RSUs wurden am 27. Oktober 2022 gewährt und sind nun vollständig vestet, es gibt keine unvested RSUs mehr unter dieser Zuteilung.

تحديث داخلي من MariMed (MRMD): أفاد رئيس العمليات Timothy Shaw بأن هناك معاملات أسهم روتينية في 27/10/2025. قام بتحويل 111,112 وحدة أسهم مقيدة إلى أسهم عادية (الرمز M؛ السعر $0)، ثم حُجز 32,612 سهمًا لتغطية الضرائب (الرمز F) بسعر $0.1579 للسهم. بعد هذه المعاملات، يمتلك شو بشكل فعّال مباشرة 9,133,912 سهمًا. كما لديه 2,000,000 سهمًا مملوكة بشكل غير مباشر بواسطة Shaw Family Trust. تم منح RSU في 27 أكتوبر 2022 وهي الآن مكتملة الاستحقاق، ولا توجد RSU غير مكتملة تحت تلك المنحة.

MariMed(MRMD)内部更新: 首席运营官 Timothy Shaw 在 2025-10-27 报告了常规股票交易。他将 111,112 股受限股票单位转换为普通股(代码 M;价格 $0),随后有 32,612 股因缴税而按代码 F 扣留,价格为每股 $0.1579。交易完成后,Shaw 直接拥有 9,133,912 股的受益所有权。他还通过 Shaw Family Trust 间接持有 2,000,000 股。RSU 于 2022 年 10 月 27 日授予,现在已完全归属,该授予下不再有未归属的 RSU。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Shaw Timothy

(Last) (First) (Middle)
C/O MARIMED INC.
10 OCEANA WAY

(Street)
NORWOOD, MA 02062

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operating Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/27/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 10/27/2025 M 111,112 A $0(1) 9,166,524 D
Common stock 10/27/2025 F 32,612(2) D $0.1579 9,133,912 D
Common stock 2,000,000 I By the Shaw Family Trust(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (RSU) (1) 10/27/2025 M 111,112 (4) (4) Common Stock, par value $.001 per share 111,112 $0 0 D
Explanation of Responses:
1. RSUs convert to shares of common stock on a one-for-one basis.
2. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.
3. The Reporting Person's spouse is the trustee of the trust and the shares held in the trust are for the benefit of the Reporting Person's children. The trust is an irrevocable trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
4. These RSUs were granted on October 27, 2022; there are no unvested RSUs remaining under this grant in accordance with the terms of an award agreement between the Issuer and the Reporting Person.
Remarks:
/s/ Timothy Shaw 10/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MRMD's COO report in the latest Form 4?

Timothy Shaw converted 111,112 RSUs to common stock (Code M) and had 32,612 shares withheld for taxes (Code F) at $0.1579.

How many MRMD shares does Timothy Shaw hold after the transactions?

He holds 9,133,912 shares directly and 2,000,000 shares indirectly via the Shaw Family Trust.

Were these MRMD transactions open-market buys or sells?

No. They reflect RSU vesting (Code M) and tax withholding (Code F), not open-market trades.

What was the source and status of the RSUs in MRMD's filing?

The RSUs were granted on October 27, 2022 and are now fully vested with none remaining unvested.

What prices were used in the MRMD Form 4 entries?

The RSU conversion was at $0; tax withholding occurred at $0.1579 per share.

What is the relationship of the indirect MRMD holdings?

The 2,000,000 shares are held by the Shaw Family Trust; beneficial ownership is disclaimed as described.
Marimed

OTC:MRMD

MRMD Rankings

MRMD Latest News

MRMD Latest SEC Filings

MRMD Stock Data

56.49M
280.32M
14.7%
0.24%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Norwood